In this issue of Clinics in Liver Disease, guest editor Robert G. Gish brings his considerable expertise to the topic of Hepatitis B and Hepatitis D. The articles provide state-of-the-art clinical summaries of the advances in Hepatitis B and D, with emphasis on HBV viro-immunology, novel assays, new targets, and tests for HBV and HDV, and more. - Contains 13 relevant, practice-oriented topics including Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B; Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus; Triple Threat: HDV, HBV, HIV Coinfection; Targeting Hepatitis B Virus DNA Using Designer Gene Editors; and more. - Provides in-depth clinical reviews on Hepatitis B and D, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

In this issue of Clinics in Liver Disease, guest editor Dr. Sammy Saab brings his considerable expertise to the topic of Hepatic Encephalopathy. Hepatic encephalopathy (HE) is a reversible syndrome in patients with advanced liver dysfunction, and is characterized by a wide spectrum of neuropsychiatric abnormalities resulting from the accumulation of neurotoxic substances in the brain. In this issue, top experts provide detailed clinical reviews devoted to the epidemiology, manifestations, and management of HE in the hopes of improving patient outcomes. - Contains 13 relevant, practice-oriented topics including clinical manifestations of HE; laboratory abnormalities of HE; pharmacologic management of HE; nontraditional treatment of HE; social impact of HE; future therapies of HE; and more. - Provides in-depth clinical reviews on hepatic encephalopathy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Clinics in Liver Disease, guest editor Dr. David E. Bernstein brings his considerable expertise to the topic of Autoimmune Hepatitis Including PBC and PSC. The three main immune disorders that involve the liver are AIH, primary biliary cholangitis, and primary sclerosing cholangitis. As these autoimmune diseases can share symptoms, it is important for the hepatologist to have clinical knowledge of each and understand their differences and similarities. This issue addresses these variants and provides the reader with important information relating to pathology, diagnosis, and treatment. - Contains 15 relevant, practice-oriented topics including autoimmune hepatitis: epidemiology, subtypes, and presentation; diagnosis of autoimmune hepatitis; treatment of autoimmune hepatitis including transplant; diagnostic tests in primary sclerosing cholangitis: serology, elastography, imaging; post-transplant management and complications of AIH, PBC, and PSC, including disease recurrence; and more. - Provides in-depth clinical reviews on autoimmune hepatitis, including PBC and PSC, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Clinics in Liver Disease, guest editor Dr. Pierre M. Gholam brings his considerable expertise to the topic of Portal Hypertension and Its Complications. Portal hypertension is often one of the major complications seen in advanced liver disease. Patients can be asymptomatic for years and considered compensated. How to manage patients prior to the point of hepatic decompensation is of utmost importance, due to the impact on life expectancy and quality. The timely clinical reviews in this issue will help hepatologists manage these patients and improve outcomes. - Contains 12 relevant, practice-oriented topics including non-invasive assessment of portal hypertension; radiological and surgical treatments of portal hypertension; bleeding complications of portal hypertension; cognitive issues and portal hypertension; surgical considerations in portal hypertension; and more. - Provides in-depth clinical reviews on portal hypertension and its complications, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.